Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending June 20, 2016. The report announces positive top-line results from the pivotal Phase III FULFIL study regarding an investigational once-daily "closed" triple combination therapy (fluticasone furoate/umeclidinium/vilanterol or FF/UMEC/VI) for patients with chronic obstructive pulmonary disease (COPD). The study was conducted in partnership with Innoviva, Inc.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory announcement focused on clinical trial results and does not contain financial statements.
Material Changes and Clinical Results
The FULFIL study met its two co-primary endpoints, demonstrating statistically significant improvements for FF/UMEC/VI compared to twice-daily Symbicort Turbohaler (budesonide/formoterol) over a 24-week period:
- Lung Function: Improvement in trough FEV1 of 171mL (95% confidence interval [148, 194], p<0.001).
- Quality of Life: Improvement in St. George's Respiratory Questionnaire (SGRQ) of -2.2 units (95% confidence interval [-3.5, -1.0], p<0.001).
- Responder Rate: 50% of patients on FF/UMEC/VI achieved the minimum clinically important difference in SGRQ (-4 units) compared to 41% on budesonide/formoterol.
Safety Profile: The safety profile was consistent with known profiles of individual medicines. At 24 weeks, serious adverse events were reported in 5.4% of FF/UMEC/VI patients versus 5.7% of comparator patients. At 52 weeks, rates were 10.0% and 12.7%, respectively.
Guidance, Outlook, and Risks
Regulatory Outlook: Findings support GSK's plan to submit a regulatory application in Europe by the end of 2016. GSK also intends to submit a New Drug Application (NDA) to the US FDA by the end of 2016.
Management Commentary: GSK and Innoviva leadership highlighted the convenience of a once-daily single inhaler compared to current multi-inhaler regimens. The IMPACT study, expected to complete in 2017, is ongoing to investigate exacerbation rates.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include potential delays in regulatory approval, clinical study outcomes differing from projections, and uncertainties regarding commercialization. The triple combination therapy is not currently approved for use anywhere in the world.
Investor Verification Checklist
- Verify the timeline for EU and US regulatory submissions (expected end of 2016).
- Monitor the ongoing IMPACT study results expected in 2017 regarding exacerbation rates.
- Review the full safety data, particularly regarding pneumonia and cardiac disorders, from the 52-week extension.
- Confirm the commercial partnership terms and royalty structures between GSK and Innoviva for future revenue recognition.
- Check for any subsequent updates on the NDA acceptance status by the FDA and EMA.